Table 3.

Responses to Alisertib

Stratum	Response Evaluable	Responder		Non-responders
		Complete Response	Partial Response	Stable Disease n patients, median (range) cycles administered	Non-responders	Progressive Disease
Neuroblastoma (Measurable)	24		1	2 (6, 13 cycles)	5	16
Neuroblastoma (MIBG Evaluable)	24	1	1	9 13 (5–35) cycles	4	9
Acute Lymphoblastic Leukemia	10			3 (1,2,2 cycles)	1	6
Acute Myeloid Leukemia	10				10
Ewing Sarcoma	10			3 (4, 5, 5 cycles)	2	5
Rhabdomyosarcoma	10			1 15 cycles	2	7
Non-Rhabdo Soft Tissue Sarcoma	10			1 5 cycles	2	7
Osteosarcoma	10				2	8
Wilms tumor	10	1		1 31 cycles	1	7
Hepatoblastoma	8		1*	1 5 cycles	2	4
Germ Cell Tumor	7			2 4 and 5 cycles	1	4
Rhabdoid Tumors	4				1	3
Total	137	2	3	23	33	76

^*Reported previously in ADVL0812 publication.³¹